The CM-sepharose assay does not require antibodies to purify myeloperoxidase from fecal samples and exploits the intrinsic enzyme activity of myeloperoxidase with the potential to deliver a sensitive point-of-care test for endoscopically determined inflammation in IBD. The gene discussed is MPO; the disease is inflammatory bowel disease.